Medtronic Recalls HeartWare HVAD System Batteries For Electrical Faults
Medtronic Plc (NYSE:MDT) is recalling HeartWare HVAD System batteries because they may experience electrical faults that cause the system to fail…
SIGA Tech Made The Smallpox Treatment As Post-9/11 Bioterrorism Defense: Report
In an effort to prevent bioterrorism attacks, just in case, SIGA Technologies Inc (NASDAQ: SIGA) started working on the smallpox treatment, Tpoxx, after the 9/11 terrorist attack that shook the world. FDA approved Tpoxx for smallpox in 2018.
Pfizer’s COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows
According to a new observational study published in the New England Journal of Medicine, Pfizer Inc's (NYSE: PFE) COVID-19 treatment, Paxlovid, only worked among patients 65 years of age or older, with
Dynavax’s Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations
Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).
With Sandoz Spinoff, Novartis Slams Brakes On Huntington’s Trial
Novartis AG (NYSE: NVS) suspended dosing in a Huntington's disease study because early signs of side effects were seen in some participants in the trial.
FDA Announced Clearance To Century Therapeutics’ Allogeneic Cell Therapy Candidate Study
Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.
Phibro Animal Clocks 16% Jump In Q4 Sales, Plans Incremental Strategic Investments In Future
Phibro Animal Health Corp (NASDAQ:PAHC) posted Q4 FY22 sales of $255.3 million, +16% Y/Y, beating the consensus of $246.02 million.…
Back-To-Back Three Japanese Approvals For AstraZeneca’s Rare Disease Treatments
The Japan regulatory authority has approved AstraZeneca Plc (NASDAQ:AZN) and Merck Co Inc’s (NYSE:MRK) Lynparza (olaparib) for the adjuvant treatment of patients with…
Lannett Clocks 30% Top-Line Decline In Q4, Forecasts Lower FY23 Sales
Lannett Company Inc (NYSE:LCI) reported Q4 FY22 sales of $74.2 million, down from $106 million a year ago, slightly below…
EXCLUSIVE: Longeveron’s Heart Disease Cell Therapy Poised To Secure European Patent
The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs).